HER-2 Expression in Pancreatic Duct Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

37 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunohistochemical Expression of PD-L1 in Pancreatic Ductal Adenocarcinoma

NCT05228808

Pancreatic Adenocarcinoma

UNKNOWN

Pancreatic Cancer Detection Consortium

NCT06388967

Pancreatic Cancer Stage II Pancreatic Cancer Stage III Pancreatic Cancer, Adult +10 more

RECRUITING

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

NCT04425876

Pancreatic Cancer

UNKNOWN PHASE1

Irinotecan Liposome in Combination With Capecitabine

NCT06578052

Pancreatic Cancer

RECRUITING NA

Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.

NCT03267173

Pancreatic Cancer CAR

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pancreatic duct adenocarcinoma (PDAC) is a deadly neoplasm that showed current increase in its occurrence. There are many challenges in PDAC; the tumor is frequently associated with perineural invasion and angioinvasion, these lead to early metastasis.Another important challenge is that the tumor is associated with extensive fibrosis that prevents arrival of chemotherapeutic agents. Most modern anti-cancer therapeutic modalities depend on the biologic signature of the tumor. Human epidermal growth factor receptor-2 (HER-2) is a cell surface protein that is associated with enhanced cellular proliferation. HER-2 has been detected and successfully targeted in many human carcinomas as breast and gastric cancers. we aimed to evaluate the potential cancer-promoting effect of HER-2 in PDAC, in order to detect any possible benefits of its targeting by future therapeutic modalities.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

immunohistochemical approach

Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cases of PDAC who underwent radical operations.
2. Tissue blocks with sufficient material.
3. Cases with available clinical data.

Exclusion Criteria

1. Cases of pancreatic carcinoma other than PDAC.
2. Patients who received preoperative chemotherapy or radiotherapy.
3. Patients with PDAC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
4. Cases with insufficient/destructed material.
5. Patients with inadequate clinical data.

Eligible Sex

ALL

Accepts Healthy Volunteers

No